<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957772</url>
  </required_header>
  <id_info>
    <org_study_id>2019 SUPRA</org_study_id>
    <nct_id>NCT03957772</nct_id>
  </id_info>
  <brief_title>The Efficacy of Extra- Versus Intrafascial Injection for Supraclavicular Brachial Plexus Block</brief_title>
  <acronym>SUPRA</acronym>
  <official_title>The Efficacy of Extra- Versus Intrafascial Injection for Supraclavicular Brachial Plexus Block: a Randomized Controlled, Single-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital du Valais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital du Valais</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized to one of two groups:

        1. Extrafascial injection group: Ultrasound-guided supraclavicular brachial plexus block
           with 2 injections of local anaesthetic, deposited at the exterior of the fascial sheath
           that surrounds the nerves

        2. Intrafascial injection group: Ultrasound-guided supraclavicular brachial plexus block
           with 2 injections of local anaesthetic, deposited at the interior of the fascial sheath
           that surrounds the nerves
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be proposed to all patients undergoing formarm or hand surgery under axillary
      brachial plexus block. Patients will be randomized to one of two groups.

      The first group - extrafascial injection group - will receive an ultrasound-guided
      supraclavicular brachial plexus block whereby the local anesthetic will be deposited at the
      exterior of the fascial sheath that surrounds the nerves.

      The second group - intrafascial injection group - will receive an ultrasound-guided
      supraclavicular brachial plexus block whereby the local anesthetic will be deposited at the
      interior of the fascial sheath that surrounds the nerves.

      All patients will receive the same type and amount of local anesthetic: 30 ml of a mixture of
      ropivacaine 0.5 % + mepivacaine 1 %.

      The primary outcome is the rate of hemidiaphragmatic paresis 30 minutes after the block
      procedure, assessed with ultrasound. Secondary outcomes are: rate of hemidiaphragmatic
      paresis 2 hours after surgery, assessed with ultrasound, bedside spirometry before the
      supraclavicular block, 30 minutes after the block and 2 hours after surgery, rate of
      successful block 30 minutes after the block , duration of sensory and motor block, pain
      scores at rest and on movement at 24 h postoperatively, cumulative postoperative opioid
      consumption at 24 hours postoperatively and patient satisfaction with overall anesthetic
      management.

      These outcomes are further defined in the section below.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The participants and all care providers will be blinded to the patient assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hemidiaphragmatic paresis 30 minutes after the block</measure>
    <time_frame>30 minutes after the block</time_frame>
    <description>Rate of hemidiaphragmatic paresis 30 minutes after the block procedure, assessed with ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemidiaphragmatic paresis 2 hours after surgery</measure>
    <time_frame>2 hours after surgery</time_frame>
    <description>Rate of hemidiaphragmatic paresis 2 hours after surgery, assessed with ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bedside spirometry before the block (baseline)</measure>
    <time_frame>30 minutes before the block</time_frame>
    <description>Bedside spirometry before the supraclavicular block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bedside spirometry after 30 minutes after the block</measure>
    <time_frame>30 minutes after the supraclavicular block</time_frame>
    <description>Bedside spirometry after the supraclavicular block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bedside spirometry 2 hours after surgery</measure>
    <time_frame>2 hours after surgery</time_frame>
    <description>Bedside spirometry 2 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful block 30 minutes after the block</measure>
    <time_frame>30 minutes after the block</time_frame>
    <description>Presence of a surgical block according to a validated composite scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Block-related side effects</measure>
    <time_frame>24 h postoperatively</time_frame>
    <description>paresthesia, dyspnea, Horner's syndrome, hoarseness, hematoma, infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during block procedure</measure>
    <time_frame>During block procedure</time_frame>
    <description>Pain score (numeric rating scale, 0-10, with 0=no pain, 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest and on movement</measure>
    <time_frame>24 h postoperatively</time_frame>
    <description>Pain score (numeric rating scale, 0-10, with 0=no pain, 10=worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Cumulative postoperative opioid consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with overall anesthetic management</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>numeric rating scale, 0-10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Upper Extremity Problem</condition>
  <arm_group>
    <arm_group_label>Extrafascial injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extrafascial injection of local anesthetic
Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrafascial injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrafascial injection of local anesthetic
Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extrafascial injection</intervention_name>
    <description>Extrafascial injection of local anaesthetic under ultrasound guidance</description>
    <arm_group_label>Extrafascial injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrafascial injection</intervention_name>
    <description>Intrafascial injection of local anaesthetic under ultrasound guidance</description>
    <arm_group_label>Intrafascial injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing forearm or hand surgery under locoregional anesthesia

          -  ASA physical status I-III

        Exclusion Criteria:

          -  Patient refusal

          -  ASA physical status IV

          -  Severe pre-existing lung disease

          -  Patient unwilling or unable to perform incentive spirometry

          -  Local anesthetic intolerance or allergy

          -  Neurological deficit or neuropathy of the arm

          -  Coagulopathy contraindicating locoregional anesthesia

          -  Malignancy or infection in the area above the clavicle

          -  Pregnancy

          -  Inability to understand the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sina Grape, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital du Valais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sina Grape, MD</last_name>
    <phone>0041276038759</phone>
    <email>sina.grape@hopitalvs.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Albrecht, MD</last_name>
    <phone>0041763281145</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital du Valais</name>
      <address>
        <city>Sion</city>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina Grape, MD</last_name>
      <phone>0041276038756</phone>
      <email>sina.grape@hopitalvs.ch</email>
    </contact>
    <contact_backup>
      <last_name>Eric Albrecht, MD</last_name>
      <phone>0041763281145</phone>
      <email>eric.albrecht@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Albrecht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>upper extremity surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no sharing of any IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

